1. Home
  2. AMBP vs PHVS Comparison

AMBP vs PHVS Comparison

Compare AMBP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardagh Metal Packaging S.A.

AMBP

Ardagh Metal Packaging S.A.

N/A

Current Price

$5.04

Market Cap

2.6B

Sector

Industrials

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$35.43

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMBP
PHVS
Founded
2021
2015
Country
Luxembourg
Switzerland
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
AMBP
PHVS
Price
$5.04
$35.43
Analyst Decision
Hold
Buy
Analyst Count
7
11
Target Price
$4.39
$41.82
AVG Volume (30 Days)
1.6M
617.5K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
10.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.31
N/A
Revenue Next Year
$2.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.29
$20.65
52 Week High
$5.47
$38.13

Technical Indicators

Market Signals
Indicator
AMBP
PHVS
Relative Strength Index (RSI) 50.07 52.36
Support Level $5.06 $24.55
Resistance Level $5.44 $36.36
Average True Range (ATR) 0.14 1.45
MACD -0.04 -0.18
Stochastic Oscillator 19.60 43.19

Price Performance

Historical Comparison
AMBP
PHVS

About AMBP Ardagh Metal Packaging S.A.

Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. The geographical segments of the company includes Europe and the Americas. Geographically, the company derives a majority of its revenue from the United States.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: